CUE Butterfly Strategy
CUE (Cue Biopharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine.
CUE (Cue Biopharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $82.5M, a beta of 2.46 versus the broader market, a 52-week range of 4.97-45.5, average daily share volume of 208K, a public-listing history dating back to 2018, approximately 29 full-time employees. These structural characteristics shape how CUE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.46 indicates CUE has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a butterfly on CUE?
A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration.
CUE snapshot
As of September 29, 2026, spot at $28.46, ATM IV 43.80%, IV rank 8.59%, expected move 12.56%. The butterfly on CUE below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this butterfly structure on CUE specifically: CUE IV at 43.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a CUE butterfly, with a market-implied 1-standard-deviation move of approximately 12.56% (roughly $3.57 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CUE expiries trade a higher absolute premium for lower per-day decay. Position sizing on CUE should anchor to the underlying notional of $28.46 per share and to the trader's directional view on CUE stock.
CUE butterfly setup
The CUE butterfly below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CUE at $28.46 on that close, the first option leg uses a $27.04 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CUE chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CUE shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $27.04 | N/A |
| Sell 2 | Call | $28.46 | N/A |
| Buy 1 | Call | $29.88 | N/A |
CUE butterfly risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit.
CUE butterfly payoff curve
Modeled P&L at expiration across a range of underlying prices for the butterfly on CUE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use butterfly on CUE
Butterflies on CUE are pinning bets - traders use them when they expect CUE to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
CUE thesis for this butterfly
The market-implied 1-standard-deviation range for CUE extends from approximately $24.89 on the downside to $32.03 on the upside. A CUE long call butterfly is a pinning play: it pays maximum at the middle strike if CUE settles there at expiration, with the wing legs capping both the cost and the maximum loss to the net debit. Current CUE IV rank near 8.59% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CUE at 43.80%. As a Healthcare name, CUE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CUE-specific events.
CUE butterfly positions are structurally neutral / pin (limited-risk, limited-reward); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CUE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CUE alongside the broader basket even when CUE-specific fundamentals are unchanged. Always rebuild the position from current CUE chain quotes before placing a trade.
Frequently asked questions
- What is a butterfly on CUE?
- A butterfly on CUE is the butterfly strategy applied to CUE (stock). The strategy is structurally neutral / pin (limited-risk, limited-reward): A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration. With CUE stock at $28.46 on the most recent close, the strikes shown on this page are snapped to the nearest listed CUE chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are CUE butterfly max profit and max loss calculated?
- Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit. For the CUE butterfly priced from the end-of-day chain at a 30-day expiry (ATM IV 43.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CUE butterfly?
- The breakeven for the CUE butterfly priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The CUE market-implied 1-standard-deviation expected move in the same options snapshot is approximately 12.56%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a butterfly on CUE?
- Butterflies on CUE are pinning bets - traders use them when they expect CUE to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
- How does current CUE implied volatility affect this butterfly?
- CUE ATM IV is at 43.80% with IV rank near 8.59%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.